Tyrosine, serine and threonine phosphorylation sites
AssigneeCell Signaling Technology, Inc.
InventorsPeter Hornbeck, Albrecht Moritz, John Rush, Steven Gygi
Life of this patent
Estimating the term…
Abstract
The invention discloses 155 novel phosphorylation sites identified in carcinoma and leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.
Claims9
An isolated phosphorylation site-specific antibody that specifically binds EZH2 only when phosphorylated at T372 comprised within SEQ ID NO:
- 34, wherein said antibody does not bind EZH2 when not phosphorylated at said T372.
An isolated phosphorylation site-specific antibody that specifically binds NDE1 only when phosphorylated at T246 comprised within SEQ ID NO:
- 26, wherein said antibody does not bind NDE1 when not phosphorylated at said T246.
An isolated phosphorylation site-specific antibody that specifically binds MAP2K1 only when phosphorylated at T388 comprised within SEQ ID NO:
- 49, wherein said antibody does not bind MAP2K1 when not phosphorylated at said T388.
Dependencies are inferred from the claim text.